On October 7, 2026 Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") reported that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Session: Advances in Oncology Panel
Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Date/time: Wednesday, October 14, 2026, from 9:00 – 10:00 a.m. ET
Location: NYY Room at the Hard Rock Hotel NYC
Mr. Klemp will discuss Moleculin’s oncology pipeline and recent clinical progress, including the Company’s lead investigational candidate, Annamycin, and its ongoing Phase 2/3 MIRACLE clinical trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML). Moleculin recently announced that Part A enrollment is completed in the MIRACLE trial, and the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.
In addition to the Company’s presentation, management will be available for meetings with institutional investors in one-on-one sessions.
This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2026-growth-summit
(Press release, Moleculin, OCT 7, 2026, View Source [SID1234673257])